SG11201903018WA - Early post-transfection isolation of cells (epic) for biologics production - Google Patents

Early post-transfection isolation of cells (epic) for biologics production

Info

Publication number
SG11201903018WA
SG11201903018WA SG11201903018WA SG11201903018WA SG11201903018WA SG 11201903018W A SG11201903018W A SG 11201903018WA SG 11201903018W A SG11201903018W A SG 11201903018WA SG 11201903018W A SG11201903018W A SG 11201903018WA SG 11201903018W A SG11201903018W A SG 11201903018WA
Authority
SG
Singapore
Prior art keywords
international
cells
rule
bridgewater
sanofi
Prior art date
Application number
SG11201903018WA
Inventor
Victor Cairns
Christine Demaria
Jason Vitko
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201903018WA publication Critical patent/SG11201903018WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70592—CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N15/149—

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 April 2018 (12.04.2018) WIP0 1 PCT omit VIII °nolo III 11010101111001010 Immo oimIE (10) International Publication Number WO 2018/067964 Al (51) International Patent Classification: C12N 15/85 (2006.01) (21) International Application Number: PCT/US2017/055583 (22) International Filing Date: 06 October 2017 (06.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/405,392 07 October 2016 (07.10.2016) US (71) Applicant: GENZYME CORPORATION [US/US]; 500 Kendall Street, Cambridge, MA 02142 (US). (72) Inventors: CAIRNS, Victor, R.; c/o Sanofi, 55 Corpo- rate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). DEMARIA, Christine; C/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). VITKO, Jason; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). (74) Agent: VELEMA, James, H. et al.; Lathrop Gage LLP, 28 State Street, Boston, MA 02109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 71- C:N (54) Title: EARLY POST-TRANSFECTION ISOLATION OF CELLS (EPIC) FOR BIOLOGICS PRODUCTION (57) : Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting 1-1 © based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, N e.g. for large-scale manufacturing of a target polypeptide of interest.
SG11201903018WA 2016-10-07 2017-10-06 Early post-transfection isolation of cells (epic) for biologics production SG11201903018WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662405392P 2016-10-07 2016-10-07
PCT/US2017/055583 WO2018067964A1 (en) 2016-10-07 2017-10-06 Early post-transfection isolation of cells (epic) for biologics production

Publications (1)

Publication Number Publication Date
SG11201903018WA true SG11201903018WA (en) 2019-05-30

Family

ID=60302441

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903018WA SG11201903018WA (en) 2016-10-07 2017-10-06 Early post-transfection isolation of cells (epic) for biologics production
SG10202103545PA SG10202103545PA (en) 2016-10-07 2017-10-06 Early post-transfection isolation of cells (epic) for biologics production

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202103545PA SG10202103545PA (en) 2016-10-07 2017-10-06 Early post-transfection isolation of cells (epic) for biologics production

Country Status (9)

Country Link
US (3) US20180119192A1 (en)
EP (1) EP3523440A1 (en)
CN (1) CN110050065B (en)
AU (2) AU2017341028B2 (en)
CA (1) CA3039598A1 (en)
MX (1) MX2019004013A (en)
SG (2) SG11201903018WA (en)
TW (2) TW202346598A (en)
WO (1) WO2018067964A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001238A1 (en) 2015-10-09 2017-04-13 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
TW202346598A (en) 2016-10-07 2023-12-01 美商健臻公司 Early post-transfection isolation of cells (epic) for biologics production

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
WO1991001374A1 (en) 1989-07-24 1991-02-07 Seragen, Inc. Prevention of internal initiation
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
AU6667798A (en) 1997-02-25 1998-09-09 Q.B.I. Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US20050005310A1 (en) 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
WO2001004306A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Expression vectors and methods
US20020058243A1 (en) 2000-02-02 2002-05-16 Kurt Jarnigan Rapid, parallel identification of cell lines
US6833254B2 (en) 2001-03-01 2004-12-21 The Regents Of The University Of California Method to identify IRES elements
DE10143237A1 (en) 2001-09-04 2003-03-20 Icon Genetics Ag Manufacture of artificial internal ribosomal entry point elements (Ires elements)
DE10143238A1 (en) 2001-09-04 2003-03-20 Icon Genetics Ag Identification of eukaryotic internal ribosome entry sites (IRES) elements
AU2003243273A1 (en) 2002-05-22 2003-12-12 Biogen Idec Ma Inc. Detection of secreted polypeptides
US7119187B2 (en) 2002-07-09 2006-10-10 National Health Research Institutes Internal ribosome entry site of the labial gene for protein expression
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2003252111A1 (en) 2002-07-19 2004-02-09 Diversa Corporation Fluorescent proteins, nucleic acids encoding them and methods for making and using them
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US20060173168A1 (en) 2002-12-16 2006-08-03 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
HUE036449T2 (en) 2003-06-24 2018-07-30 Genzyme Corp Novel Beta-Actin and RPS21 promoters and uses thereof
US7776584B2 (en) 2003-08-01 2010-08-17 Genetix Limited Animal cell colony picking apparatus and method
US20070178072A1 (en) 2004-03-31 2007-08-02 Kirin Beer Kabushiki Kaisha Method for inducing differentiation of regulatory t cells usinggip-anchored protein agonist and pharmaceutical composition therefor ( as amended
US7078179B2 (en) 2004-05-04 2006-07-18 Newlink Genetics Corporation Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase
US20060172382A1 (en) 2004-11-08 2006-08-03 Chromagenics B.V. Selection of host cells expressing protein at high levels
KR101271884B1 (en) 2004-11-08 2013-06-05 크로마제닉스 비.브이. Selection of host cells expressing protein at high levels
CA2588936A1 (en) * 2004-12-14 2006-06-22 F. Hoffmann-La Roche Ag Method for improved selection of rnai transfectants
CA2648778A1 (en) * 2006-04-10 2007-10-18 The Regents Of The University Of California Method for culturing cells on removable pallets for subsequent cell expansion and analysis
ES2388003T3 (en) 2006-09-20 2012-10-05 Genzyme Corporation A system based on FACS and the indicator protein for high-performance development of therapeutic proteins
EP2136817A4 (en) 2007-03-05 2010-08-18 Newsouth Innovations Pty Ltd Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents
CN102459607B (en) * 2009-06-15 2014-08-06 萨拉基尼克有限公司 Novel stringent selectable markers
US9534246B2 (en) 2010-07-01 2017-01-03 Glaxo Group Limited Method for selecting high producing cell lines
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US20160017319A1 (en) 2013-03-11 2016-01-21 Audrey Nommay Method of screening cell clones
CA3001238A1 (en) * 2015-10-09 2017-04-13 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
TW202346598A (en) 2016-10-07 2023-12-01 美商健臻公司 Early post-transfection isolation of cells (epic) for biologics production

Also Published As

Publication number Publication date
MX2019004013A (en) 2019-08-14
US20240026410A1 (en) 2024-01-25
CA3039598A1 (en) 2018-04-12
AU2017341028B2 (en) 2023-12-21
TWI795373B (en) 2023-03-11
US20180119192A1 (en) 2018-05-03
TW202346598A (en) 2023-12-01
US11685943B2 (en) 2023-06-27
AU2017341028A1 (en) 2019-05-23
US20200299743A1 (en) 2020-09-24
SG10202103545PA (en) 2021-05-28
CN110050065B (en) 2024-05-07
TW201827598A (en) 2018-08-01
EP3523440A1 (en) 2019-08-14
WO2018067964A1 (en) 2018-04-12
CN110050065A (en) 2019-07-23
AU2024201853A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201902925PA (en) Phenotype/disease specific gene ranking using curated, gene library and network based data structures
SG11201808678QA (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions
SG11201803169WA (en) Cellulase variants and polynucleotides encoding same
SG11201909931PA (en) Oligomeric particle reagents and methods of use thereof
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201907653QA (en) Compositions and methods for enhanced gene expression
SG11201908489XA (en) De novo synthesized combinatorial nucleic acid libraries
SG11201807426WA (en) Immunomodulators
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201903825SA (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
SG11201906213UA (en) Modulating expression of polypeptides via new gene switch expression systems
SG11201811405QA (en) Improved differentiation method
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201806398YA (en) Optimized factor viii genes
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201806758VA (en) Vcn enhancer compositions and methods of using the same
SG11201907319QA (en) Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201808476SA (en) Recycling of polymer matrix composite